Extended-Release Drugs Global Market Report 2023 – By Type (Sustained Release Drug, Controlled Release Drug), By Mode (Over-The-Counter, Prescription), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores) – Market Size, Trends, And Global Forecast 2023-2032

Drug of abuse (DOA) testing refers to the examination of a substance, such as a drug, chemical, or plant product, that is usually treated recreationally. It includes marijuana, cocaine, opioids, amphetamines, alcohol, and PCP, which are tested for on a drug panel. The patient's urine, saliva, blood, hair, or sweat are used in this clinical screening procedure. The main products and services for drug of abuse (DOA) testing are analyzers, rapid testing devices, consumables, and laboratory services. An analyzer is a device that automatically measures the chemical concentration of one or more components or another associated physical quantity, continuously or intermittently. There are sample types included such as urine, hair, oral fluid, and breath, and are available in various applications such as pain management, criminal justice, and workplace screening. The end users involve hospitals, diagnostic laboratories, forensic laboratories, and others. The global drugs of abuse (DOA) testing market is segmented - 1) By Product And Service: Analyzers, Rapid Testing Devices, Consumables, Laboratory Services 2) By Sample Type: Urine, Hair, Oral Fluid, Breath 3) By Application: Pain Management, Criminal Justice, Workplace Screening 4) By End User: Hospitals, Diagnostic Laboratories, Forensic Laboratories, Other End Users The global drugs of abuse (DOA) testing market size is expected to grow from $6.03 billion in 2022 to $6.65 billion in 2023 at a compound annual growth rate (CAGR) of 10.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The global drug of abuse (DOA) testing market size is expected to reach $9.35 billion in 2027 at a CAGR of 8.9%. Increasing demand for drug abuse treatment is expected to propel the growth of the drugs of abuse (DOA) testing market going forward. Drug abuse or substance abuse refers to the use of a substance in quantities that are harmful to the user or others. Drug testing aids in the identification of compounds that are not normally found in the body. The process starts with a screening test, which is followed by a second test to find and/or confirm the presence of a substance or substances, so increasing demand for drug abuse treatment will propel the market's growth. For instance, in June 2021, according to United Nations Office on Drugs and Crime (UNODC), a US-based drug control and crime prevention organization, combining the United Nations International Report 2021 World Drug Report, over 36 million individuals in the world have drug use disorders, and over 275 million people used drugs in 2020. Therefore, increasing demand for drug abuse treatment is driving the drug of abuse (DOA) testing market. Major players in the drugs of abuse (doa) testing market are Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings, Dragerwerk AG & Co. KGaA, Quest Diagnostics Inc., United States Drug Testing Laboratories Inc., Thermo Fisher Scientific Inc., Siemens Healthcare Private Limited, F. Hoffmann-La Roche Ltd, Cordant Health Solutions, Omega Laboratories Inc., Psychemedics Corporation, Zimmer Biomet, Homology Medicines Inc., and bioMérieux Inc. Technology advancement is a key trend gaining popularity in the drugs of abuse (DOA) testing market. Major companies operating in the drugs of abuse (DOA) testing market are focused on developing new technological solutions to strengthen their position in the market. For instance, in May 2020, a Canada-based technology company created instruments to detect THC in breath for law enforcement. Cannabix Technologies' point-of-care breath testing solutions is used for the detection of 9-tetrahydrocannabinol ("THC"), the psychoactive element in marijuana that contributes to impairment, are at the forefront of industry research and development. The THCBA detects THC in breath using microfluidic sensor technology. The THCBA includes appealing features such as single-stage direct breath capabilities and a one-handed ergonomic design. So far, testing has shown that the device can produce results in less than 5 minutes from the time the sample is eaten. In June 2020, Medix Biochemica, a Finland-based biotechnology company, acquired Biostride Inc. for an undisclosed amount. With this acquisition, Biostride's array of drug of abuse antibodies and antigens is now available to IVD and drug testing customers worldwide. The acquisition is consistent with Medix's plan to streamline the IVD supply chain and emerge as the industry's top provider of vital raw materials. Biostride Inc. is a US-based producer of antibodies and antigens for the IVD industry for drugs of abuse and hormone testing. North America was the largest region in the drugs of abuse (DOA) testing market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global drugs of abuse (DOA) testing market report during the forecast period. The regions covered in the global drugs of abuse (DOA) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drugs of abuse (DOA) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The drugs of abuse (DOA) testing market includes revenues earned by entities by providing services such as analyzers, rapid testing devices, consumables, and laboratory services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drugs of abuse (DOA) testing market research report is one of a series of new reports from. The Business Research Company that provides drugs of abuse (DOA) testing market statistics, including drugs of abuse (DOA) testing industry global market size, regional shares, competitors with a drugs of abuse (DOA) testing market share, detailed drugs of abuse (DOA) testing market segments, market trends and opportunities, and any further data you may need to thrive in the drugs of abuse (DOA) testing industry. This drug of abuse (DOA) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Controlled release drug delivery refers to a dosage form that administers a medicine or medication in a specified way. This drug delivery method continuously delivers pharmaceuticals or medications in predictable kinetics for the predetermined time. The main types of technology used in controlled release drug delivery are the wurster technique, coacervation, micro encapsulation, implants, transdermal, targeted delivery, and others. The wurster technique, often referred to as fluid bed microencapsulation is the encapsulation of discrete particles in a fluidized bed employing differential air flow to produce cyclic movement of material. It involves several release mechanisms such as polymer-based systems, micro-reservoir partition-controlled drug delivery systems, feedback-regulated drug delivery systems, activation-modulated drug delivery systems, and chemically activated, which are used in applications such as metering dose inhalers, injectables, transdermal and ocular patches, and others. Major end-users include hospitals, clinics, personal, research, and others. The global controlled release drug delivery market is segmented - 1) By Technology: Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, Other Technologies 2) By Release Mechanism: Polymer Based Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Feedback Regulated Drug Delivery Systems, Activation-Modulated Drug Delivery Systems, Chemically Activated, 3) By Application: Metered Dose Inhalers, Injectable, Transdermal and Ocular Patches, Other Applications 4) By End User: Hospitals, Clinics, Peronal, Research, Other End Users The global controlled release drug delivery market size is expected to grow from $52.93 billion in 2022 to $59.20 billion in 2023 at a compound annual growth rate (CAGR) of 11.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global controlled release drug delivery market size is expected to reach $92.60 billion in 2027 at a CAGR of 11.8%. The rising prevalence of chronic diseases is expected to propel the growth of the controlled release drug delivery market. Chronic diseases are also known as noncommunicable diseases. It refers to conditions such as heart disease, cancer, and diabetes diseases lasting more than a year and requiring continuing medical care, limiting everyday activities, or both. Controlled-release drug delivery is crucial for treating chronic diseases. For patients with chronic illnesses that require years of treatment or those who reside in areas with limited resources and access to healthcare, drug delivery formulations that allow prolonged medication release are essential. For instance, in September 2022, according to report shared by the World Health Organization (WHO), a Switzerland-based health-specialized agency, every year, 41 million people die from chronic diseases, which accounts for 74 percent of all fatalities worldwide. Before the age of 70, 17 million individuals lose their lives to chronic illnesses. Moreover, 77 percent of deaths from chronic diseases occur in low- and middle-income nations. And these numbers are expected to rise in the future. Therefore, the rising prevalence of chronic diseases is driving the growth of the controlled release drug delivery market. Major players in the controlled release drug delivery market are Johnson And Johnson, Merck And Co. Inc., Alkermes Plc., Coating Place Inc., Corium International Inc., Depomed Inc., Pfizer Inc., Aradigm Corporation, Capsugel, GlaxoSmithKline Plc., Bayer Healthcare LLC, Collegium Pharmaceuticals, GE Healthcare, Adare Pharma Solutions, Allergan Plc., and Novartis AG. Technological advancement is a key trend gaining popularity in the controlled-release drug delivery market. Major companies operating in the controlled-release drug delivery market are adopting new technologies to sustain their position in the market. For instance, in October 2020, Evonik Industries AG, a Germany-based pharmaceutical manufacturer, launched Eudratec Fasteric, an oral drug delivery technology that increases gastric resistance and improves intestinal absorption for oral drug products that target sites in the upper small intestine, where there is a narrow absorption window. Moreover, it may be processed quickly and easily using common tools and is appropriate for use with a variety of oral dosage forms, including multiarticulate, tablets, and capsules. In May 2020, Adare Pharmaceutical Inc., a US-based pharmaceutical company that provides advanced pharmaceutical technologies, acquired Orbis Biosciences Inc., for an undisclosed amount. With these acquisition, Adare Pharmaceutical Inc hopes to extend its platforms to create drug particles that can be dosed in oral liquid, intravenous, and otic dosage forms and widen its product offerings. Orbis Biosciences Inc. is a US-based biotech company that develops controlled-release delivery technologies for the oral drug, medical, chemical, and consumer product industries to improve compliance. North America was the largest region in the controlled release drug delivery market in 2022. The regions covered in the global controlled release drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the controlled release drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The controlled release drug delivery market consists of revenues earned by entities by providing services such as mucoadhesive drug delivery, implantable drug delivery, and gastro-retentive drug delivery. The market value includes the value of related goods sold by the service provider or included within the service offering. The controlled release drug delivery market also includes sales of nebulizers, infusion pumps, and other systems used to provide controlled release drug delivery. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The controlled release drug delivery market research report is one of a series of new reports from The Business Research Company that provides controlled release drug delivery market statistics, including controlled release drug delivery industry global market size, regional shares, competitors with a controlled release drug delivery market share, detailed controlled release drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the controlled release drug delivery industry. This controlled release drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sustained-release excipients refer to pharmaceutical ingredients or additives used in the formulation of drug delivery systems designed to achieve controlled or sustained release of active pharmaceutical ingredients (APIs) over an extended period of time. These excipients play a crucial role in controlling the release rate and duration of drug action, thereby optimizing therapeutic efficacy and patient compliance. The main types of sustained-release excipient products are gelatin, polymers, minerals, sugars, alcohol, and chitosan. Gelatin refers to a protein derived from collagen, which is the most abundant protein in animal connective tissues such as skin, bones, and tendons. These are administered through various routes, including oral, intramuscular, subcutaneous, transdermal, vaginal, ophthalmic, intravenous, and others. Several types of technologies are involved, such as targeted delivery, microencapsulation, the Wurster technique, transdermal, implants, and coacervation. The global sustained release excipients market is segmented - 1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan 2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration 3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation The global sustained release excipients market size is expected to grow from $1.18 billion in 2022 to $1.29 billion in 2023 at a compound annual growth rate (CAGR) of 9.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global sustained release excipients market size is expected to reach $1.80 billion in 2027 at a CAGR of 8.6%. The increasing prevalence of chronic and acute diseases is expected to propel the growth of the sustained-release excipients market going forward. Chronic and acute diseases are two distinct categories used to classify different illnesses based on their duration and progression. Chronic diseases are long-lasting medical conditions that persist over an extended period, typically three months or more. Acute diseases are characterized by a rapid onset of symptoms that are usually severe but short-lived. These diseases develop suddenly and generally last briefly, ranging from hours to days or weeks. Sustained-release excipients are widely used to formulate pharmaceutical products for both chronic and acute diseases. It improves patient adherence, maintains consistent drug levels, reduces side effects, and improves disease management, so these factors boost the sales of sustained-release excipients. For instance, in September 2022, according to the World Health Organization (WHO), a Switzerland-based specialized health agency, cardiovascular diseases accounted for most NCD deaths, or 17.9 million people annually, followed by chronic respiratory illnesses (4.1 million), diabetes (2.0 million, including fatalities from renal disease brought on by diabetes), and cancer (9.3 million). Furthermore, in October 2022, according to an article published by the Pan American Health Organization, a US-based international public health agency, approximately 10.6 million people fell ill with tuberculosis (TB) in 2021, an increase of 4.5% from 2020. Therefore, the increasing prevalence of chronic and acute diseases drives the growth of the sustained-release excipients market. Major players in the sustained release excipients market are Mylan N.V., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Ashland Global Holdings, BASF Corporation, Croda International PLC, GlaxoSmithKline PLC, Evonik Industries, Gattefosse SAS, International Flavors And Fragrances Inc., Merck KGaA, AstraZeneca PLC, Colorcon Inc., and Salix Pharmaceuticals Inc. Product innovation is the key trend gaining popularity in the sustained release excipients market. Major companies operating in the sustained release excipients market are developing innovative products to strengthen their position in the market. For instance, in September 2022, Nutriventia Limited, an India-based pharmaceutical company, launched Prolanza, a sustained-release ashwagandha ingredient (Withania somnifera). It is an advanced Ashwagandha root-only extract that offers continuous stress-reduction support. Prolanza's unique release mechanism allows it to exhibit its therapeutic effects over an extended period with just one dose each day. IProlanza ashwagandha demonstrated better relative absorption, improved bioavailability, and a longer elimination half-life when compared to the control component, indicating a sustained-release profile. Prolanza's therapeutic effects will last longer and have a higher overall good influence on health because ashwagandha is primarily used for its capacity to adapt and lessen stress responses. It's manufactured from natural herbs and has been clinically confirmed to work. In December 2021, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired Arena Pharmaceuticals for approximately $6.7 billion. The acquisition of Arena strengthens Pfizer's abilities as well as its experience in inflammation and immunology, a Pfizer innovation engine that creates viable treatments for patients with crippling immuno-inflammatory illnesses who require better treatment alternatives. Arena Pharmaceuticals is a US-based producer of sustained-release drug formulations. North America was the largest region in the global sustained release excipients market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered is sustained-release excipients report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the sustained-release excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The sustained-release excipients market consists of sales of ethyl cellulose, lipid-based excipients, waxes, fatty acids, polyethylene glycol (PEG), copovidone, and osmotic agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The sustained release excipients market research report is one of a series of new reports from The Business Research Company that provides sustained release excipients market statistics, including sustained release excipients industry global market size, regional shares, competitors with a sustained release excipients market share, detailed sustained release excipients market segments, market trends and opportunities, and any further data you may need to thrive in the sustained release excipients industry. This sustained release excipients market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drugs for hormonal replacement therapy are used to treat patients with growth hormone deficiency caused due to conditions such as dwarfism or menopause (a condition that describes changes a woman goes through when her menstruating cycle stops). The drugs for hormonal replacement therapy help to replace low-level hormones from the body, maintain growth hormone deficiency and prevent women from vaginal dryness, mood swings, weakening of bones, and others. The main types of drugs for hormonal replacement therapy are estrogen replacement therapy, human growth hormone (HGH) replacement therapy, thyroid replacement therapy, and testosterone replacement therapy. The various routes of administration are oral, parental, and others which are distributed in hospital pharmacies, retail pharmacies, and online pharmacies. The therapies are applied for hypothyroidism, male hypogonadism, growth hormone deficiency, menopause, and others. The global drugs for hormonal replacement therapy market is segmented - 1) By Therapy Type: Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, Other Applications 4) By Route of Administration: Oral, Parental, Other Route of Administration The global drugs for hormonal replacement therapy market size will grow from $12.01 billion in 2022 to $12.66 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global drugs for hormonal replacement therapy is expected to grow to $14.63 billion in 2027 at a CAGR of 3.7%. The increasing population of aging and postmenopausal women is driving the drugs for hormonal replacement therapy market . Hormonal replacement therapy drugs such as estrogen, progesterone, and others are used to treat medical conditions caused by menopausal conditions. For instance, in February 2021, according to the United Nations Economic and Social Commission for Asia and the Pacific, a Thailand-based regional commission, over half of the people who are over 65 are women, making up over 9% of the total population. By 2050, this percentage is projected to nearly double to more than 18%. From 1.7% to 4.9% of the population, the proportion of people over 80 will almost treble, with women making up over 60% of this group. There are a number of factors that could make older women more vulnerable than older men, including: According to the European Menopause and Andropause Society (EMAS) report, women aged over 60 are expected to reach over 1 billion by 2050. In South Korea, the female population is expected to exceed the male population by 2060, out of which 59.6% of the female population is expected to suffer from postmenopausal symptoms. Thus, the growing female population suffering from menopausal symptoms and the aging population drive the growth of drugs for hormonal replacement therapy market Major players in the drugs for hormonal replacement therapy market are Novartis AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Abbott, Mylan Laboratories, Merck & Co., Hisamitsu Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Noven Pharmaceuticals Inc., Orion Pharma AB, Allergan PLC., QuatRx Pharmaceuticals, Wyeth, Amgen Inc., Roche, Genentech, and TherapeuticsMD. Increasing the occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder the growth of drugs for hormonal replacement therapy market. The side effects include vagina dryness, irregular heartbeat, breast swelling, osteoporosis (weakening of bones), and other effects when women undergo hormone replacement therapy. A high dosage of drugs for hormonal replacement therapy may cause rapid heartbeat, bloating (a build-up of gas in the stomach and intestines), nausea, indigestion, vaginal bleeding, blood clots, heart attack, breast cancer, and others. According to an online study, a decrease in the intake of drugs for combined hormone therapy showed a decrease in breast cancer cases by 126,000 and cardiovascular disease cases by 76,000. Thus, the increasing side effects of drugs hinder the growth of drugs for hormonal replacement therapy. Companies in the drugs for hormonal replacement therapy industry are increasingly developing of drugs for hormonal replacement therapy market with better safety profiles and novel drug delivery mechanisms. The drug delivery mechanisms include transdermal estrogen, virginal estrogen, and others. Transdermal estrogen drug delivery is in the form of estradiol transdermal gel, patch, and spray that are used to treat symptoms of menopause, vaginal dryness, itching, burning and others that occur due to low estrogen levels. Varginalestrogen in the form of cream, vaginal ring, and vaginal tablets is used to get the hormone estrogen into the system. For instance, Novo Nordisk, a multinational pharmaceutical company provides novel drug delivery mechanisms and low-dose drugs for hormonal replacement therapy (HRT) to cater to the rising demand of patient needs. Some of the brand’s offerings of novel drugs include Climara, Divigel, Elestrin, Esclim, Estraderm, Estrasorb, EstroGel, Evamist, Oesclim, Rhoxal-EstradiolDerm 50, Vivelle 100 Mcg, Estradot Transdermal Therapeutic System, and others. Department Of Health and Human Services of the Food and Drug Administration (FDA), a federal agency, is a regulatory body that monitors, controls, and regulates the drugs for hormone replacement therapy market. For instance, the FDA's Department Of Health and Human Services has revised the requirements for specific hormone-containing drug products for human use. These hormones include estrogens, progestins, androgens, anabolic steroids, adrenal corticosteroids, and synthetic analogs. The purpose of the revisal of existing regulations by the FDA is to establish the effectiveness and ensure safety for any over-the-counter drug use of these ingredients. North America was the largest region in the drugs for hormonal replacement therapy market in 2022. The Middle East is expected to be the fastest-growing region in the global drugs for hormonal replacement therapy market share during the forecast period. The regions covered in the global drugs for hormonal replacement therapy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for hormonal replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The drugs for hormonal replacement therapy market includes revenues earned by entities by treating common menopausal symptoms, including hot flashes and vaginal discomfort. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The drugs for hormonal replacement therapy market research report is one of a series of new reports from The Business Research Company that provides drugs for hormonal replacement therapy market statistics, including drugs for hormonal replacement therapy industry global market size, regional shares, competitors with drugs for hormonal replacement therapy market share, detailed drugs for hormonal replacement therapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for hormonal replacement therapy industry. This drugs for hormonal replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drugs for immunotherapy refer to a kind of medication that offers treatment to either stimulate or suppress the immune system in order to aid the body's protection against cancer, infection, and other disorders. Your immune system is assisted in fighting cancer via immunotherapy, a sort of cancer treatment. The body's immune system aids in the fight against infections and other disorders. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and they are used by various sectors such as hospitals and clinics, ambulatory surgical centers, and others. The global drugs for immunotherapy market is segmented - 1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types 2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users The global drugs for immunotherapy market size grew from $208.56 billion in 2022 to $231.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global drugs for immunotherapy is expected to grow from $349.53 billion in 2027 at a CAGR of 10.9%. The drugs for immunotherapy market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. For instance, in February 2022, according to a report shared by the WHO, a Switzerland-based specialized agency of the United Nations responsible for international public health, roughly 10 million deaths, or nearly one in six deaths, will be caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the drugs for immunotherapy market growth. Major players in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen, Inc., AbbVie, Inc., and Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca PLC., Johnson & Johnson, and UbiVac. The high cost of drugs for the immunotherapy market is acting as a restraint on the drugs for the immunotherapy market as a smaller number of patients can afford the treatment. Immunotherapy drugs are expensive as they are made specifically for each patient, and investment costs in research and development are high. For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient, depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer, costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes them unaffordable, thereby affecting the drugs for immunotherapy market growth. Manufacturers of drugs for immunotherapy market are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilise Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy. Manufacturers of drugs for immunotherapy market are governed by various regulatory bodies, such as the Food and Drug Administration in the USA. The Food and Drug Administration (FDA) regulates drugs and biologics under the authority granted to it by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its amendments. Under this authority, FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics, depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins, and some nucleic acids. In August 2020, Bristol Myers Squibb, a US-based pharmaceutical company that manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders, acquired Dragonfly Therapeutics’ investigational immunotherapy program for $475 million. Through this acquisition, Bristol Myers Squibb will be granted Dragonfly’s extended half-life cytokine DF6002, a monovalent IL-12 immunoglobulin Fc. Dragonfly Therapeutics, Inc. is a US-based discovery-stage company developing drugs to stimulate immune responses against cancer. North America was the largest region in the immunotherapy market in 2022. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA. The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The drug benign prostatic hypertrophy refers to benign prostatic hypertrophy drugs that are used to treat enlarged prostate glands by relaxing bladder neck muscles and muscle fibres in the prostate, making urination easier. Benign Prostatic Hypertrophy is commonly seen in men older than 50. The main types of drugs for benign prostatic hypertrophy are alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and others. Alpha-blockers, commonly known as "blockers" or "adrenoreceptor antagonists," are a type of pharmaceutical drug that works by blocking adrenergic receptors. The different sectors include hospital pharmacies, retail pharmacies, and others and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. The global drugs for benign prostatic hypertrophy market is segmented - 1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types 2) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global drugs for benign prostatic hypertrophy market size will grow from $6.45 billion in 2022 to $6.86 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global drugs for benign prostatic hypertrophy is expected to grow to $8.18 billion in 2027 at a CAGR of 4.5%. The rising male geriatric population globally is driving the growth of drugs for benign prostatic hypertrophy market for Benign Prostatic Hypertrophy drugs as the condition is commonly seen in men aged over 50 years. According to the United Nations' 2019 World Population Ageing Report, the number of people aged 65 years or above was 703 million in 2019 and is expected to double to around 1.5 billion by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years. Major players in the drugs for benign prostatic hypertrophy market are Allergan PLC., Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC., Teva Pharmaceutical Industries Limited, Sanofi, Nymox Pharmaceutical Corporation, and AEternaZentaris Inc. Increasing adoption of minimally invasive surgeries due to advancements in technology is restraining the growth of the Benign Prostatic Hyperplasia drugs market. Minimally invasive surgeries cause less pain and are generally conducted on an outpatient basis. This eliminates the need to consume Benign Prostatic Hyperplasia drugs, acting as a restraint on the market. Some of the minimally invasive surgeries used to treat Benign Prostatic Hyperplasia include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT), and transurethral needle ablation (TUNA). Combination drugs are increasingly being used in the treatment of Benign Prostatic Hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects, and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of Benign Prostatic Hypertrophy. Benign prostatic hypertrophy drug manufacturers globally are regulated by various regulatory bodies. For instance, in the European Union, the EU legislation authorizes medicines based on quality, safety, and efficacy. Companies are mandated to submit compliance documentation for suitable quality before applying for authorization. Manufacturers are required to demonstrate the safety and efficacy of drugs using clinical trial data, which will be assessed by competent authorities before authorizing for sale. North America was the largest region in the drugs for benign prostatic hypertrophy market in 2022. Middle East is expected to be the fastest-growing region in the global drugs for benign prostatic hypertrophy market share. The regions covered in the global drugs for benign prostatic hypertrophy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Controlled-release fertilizers (CRFs) are granular fertilizer particles covered with a resin or polymer that limits moisture contact and serves to dissolve the fertilizer particles, allowing the fertilizer to be released gradually over time. The controlled release fertilizer are highly advantageous for agriculture, silviculture, and horticulture. The main product types of controlled release fertilizers are polymer sulfur-coated urea/sulfur-coated urea, polymer-coated urea, and polymer-coated NPK. Polymer-coated urea is urea granules that have been coated with a polymer that inhibits urea release into the soil. The controlled release fertilizers are available in liquid, a granular and powdered form that is used for foliar, fertigation, soil, and other applications. The various end-uses include agriculture, cereals and grains, oilseeds and pulses, vegetables, fruits, and plantation crops. The global controlled release fertilizer market is segmented - 1) By Product: Polymer Sulfur Coated Urea/Sulfur Coated Urea, Polymer Coated Urea, Polymer Coated NPK 2) By Form: Liquid, Granular, Powder 3) By Application: Foliar, Fertigation, Soil, Other Applications 4) By End-Use: Agriculture, Cereals And Grains, Oilseeds And Pulses, Vegetables, Fruits And Plantation Crops The global controlled release fertilizer market size grew from $2.84 billion in 2022 to $3.04 billion in 2023 at a compound annual growth rate (CAGR) of 6.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The market size of the global controlled release fertilizer is expected to grow to $3.95 billion in 2027 at a CAGR of 6.7%. The increasing adoption of modern agriculture practices is significantly driving the growth of the controlled release fertilizer market. Modern agriculture is an expanding approach to agricultural inventions and farming practices that assist farmers to boost efficiency and minimize the number of natural resources needed to meet the world's food, fuel, and fiber demands, such as water, land, and energy. Controlled release fertilizers examine precision fertilizer applications utilizing the 4-R approach-the right amount of fertilizer at the right time to the right plant at the right stage of growth. For instance, in July 2022, according to a report published by Khulna University Studies, a Bangladesh-based organization on research and academics, on average, the farmers in the survey have been farming for more than 23 years. According to study findings, 87 percent of farming households in the study area are using modern technologies to manage irrigation, use better seeds, and use chemical fertilizers. Around 60% of people are using harvesting technology today. Hence, the increasing adoption of modern agriculture practices is expected to propel the growth of the controlled release fertilizer market going forward. Major players in the controlled release fertilizer market are Yara International, Agrium Inc., Kingenta Ecological Engineering Co. Ltd., ICL Group, Haifa Chemicals, Scotts Miracle-Gro Company, Nutrien, Koch Industries, Compo Expert, Helena Agri-Enterprises LLC, JNC Corporation, Sociedad Química y Minera de Chile, Ekompany International B.V, Jcam Agri, Aglukoon, and Greenfeed Agro Sdn Bhd. Technological advancement is a key trend gaining popularity in the controlled release fertilizer market. Major companies operating in the controlled release fertilizer sector are focused on developing technologically advanced products to strengthen their position. For instance, in September 2021, ICL Group, an Israel-based company that develops, produces, and markets fertilizers, metals, and other special-purpose chemical products, introduced the fifth version of its Osmocote controlled-release fertilizer. Osmocote 5 has a distinctive nutrient matching release technology as well as an upgraded Optimised Trace Element Availability (OTEA) system that matches plants' needs throughout the release program, resulting in increased plant health, color, and growth. Considering the inclination to minimize or remove peat, Osmocote 5 has a slightly increased Nitrogen concentration to enhance growth. In October 2021, Profile Products LLC, a US-based manufacturer and supplier of hydraulically applied erosion control technologies, soil modifiers, turf establishment blankets, and turf reinforcement mats, acquired Florikan for an undisclosed amount. This acquisition strengthens both firms' agronomic knowledge and expands Profile's capacity to address clients' product and service needs across all of the company's business sectors. Florikan is a US-based company that makes controlled-release fertilizers and designs specialized coatings to encapsulate nutrients while enhancing plant nutrition and lowering environmental effects. The Asia-Pacific was the largest region in the controlled release fertilizer market in 2022 and is expected to be the fastest-growing region in the forecast period. The regions covered in the controlled release fertilizer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the controlled release fertilizer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The controlled release fertilizer market consists of sales of controlled-release fertilizer products such as urea formaldehyde and crotonylidenediurea. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The controlled release fertilizer market research report is one of a series of new reports from The Business Research Company that provides controlled release fertilizer market statistics, including controlled release fertilizer industry global market size, regional shares, competitors with a controlled release fertilizer market share, detailed controlled release fertilizer market segments, market trends and opportunities, and any further data you may need to thrive in the controlled release fertilizer industry. This controlled-release fertilizer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Extended reality (XR) refers to a spectrum of technologies that merge the physical and virtual worlds to create immersive and interactive experiences. XR encompasses virtual reality (VR), augmented reality (AR), and mixed reality (MR), allowing users to engage with digital content and interact with virtual objects or environments in real time. The main components of extended reality are hardware, software, and services. Hardware components refer to the physical devices and equipment used in extended reality. The various technologies include augmented reality (AR) technology, virtual reality (VR) technology, and mixed reality (MR) technology that is used by various end users such as gaming, retail, healthcare, manufacturing, media and entertainment, education, aerospace and defense, and others. The global extended reality market is segmented - 1) By Component: Hardware, Software, Services 2) By Technologies: Augmented Reality (AR) Technology, Virtual Reality (VR) Technology, Mixed Reality (MR) Technology 3) By End User: Gaming, Retail, Healthcare, Manufacturing, Media And Entertainment, Education, Aerospace And Defense, Other End Users The global extended reality market is expected to grow from $34.56 billion in 2022 to $44.62 billion in 2023 at a compound annual growth rate (CAGR) of 29.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The extended reality market is expected to reach $123.77 billion in 2027 at a CAGR of 29.1%. Increasing government initiatives in extended reality (XR) are expected to propel the growth of the extended reality (XR) market going forward. Government initiatives are the initiatives various governments take to support a particular industry or area in a country. Several government authorities, such as the Dubai government, are initiating several initiatives for the development of extended reality and thereby supporting the country’s digital transformation. For instance, in July 2022, the Dubai government initiated a significant metaverse strategy. This initiative aims at becoming one of the top 10 extended reality (XR) economies to create a network of virtual spaces and improve the quality of life for citizens with metaverse technologies. Therefore, increasing government initiatives in extended reality (XR) drives the extended reality (XR) market. Major players in the extended reality market are Apple Inc., Google LLC, Samsung Electronics Co. Ltd., Microsoft Corporation, Meta Platforms Inc., Sony Corporation, Accenture plc, Qualcomm Incorporated, NVIDIA Corporation, Adobe Inc., Seiko Epson Corporation, Dassault Systemes SE, PTC Inc., Unity Technologies Inc, SoftServe Inc., Tata Elxsi Ltd., Semcon AB, HTC Corporation, Northern Digital Inc., Varjo Technologies Oy, Talespin Reality Labs Inc., Ultraleap Ltd, Marxent Labs LLC, Vuzix Corporation, Avegant Corporation, Virtuix Inc., Worldviz LLC, Sixense Enterprises Inc., Daqri LLC, and The Void LLC. Product innovations are a key trend gaining popularity in the extended reality market. Major companies operating in the extended reality market are innovating new products to sustain their position in the market. For instance, in June 2023, Apple Inc., a US-based technology, launched Apple Vision Pro, a spatial computer that seamlessly merges digital content with the physical world. It features an ultra-high-resolution display system controlled by a user's eyes, hands, and voice, offering an intuitive and natural input system. The device runs on Vision, a spatial operating system that enables multitasking and infinite screen real estate. Vision Pro revolutionizes personal computing with its advanced hardware and software technologies by creating an immersive and interactive computing environment. In May 2021, Snap Inc, a US-based camera and social media company, acquired WaveOptics for $500 million. The acquisition helped Snap Inc by securing exclusive access to the startup's AR technology, enabling Snap to enhance its Spectacles augmented reality glasses and maintain a leading position in the social AR hardware space. WaveOptics is a UK-based designer and manufacturer of diffractive waveguides for wearable Augmented Reality (AR) devices. North America was the largest region in the extended reality market in 2022. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in extended reality (XR) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the extended reality (XR) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The extended reality (XR) market consists of revenues earned by entities by providing consumer engagement, and business engagement. The market value includes the value of related goods sold by the service provider or included within the service offering. The extended reality (XR) market also includes sales of AR devices, VR devices, and MR devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The extended reality market research report is one of a series of new reports from The Business Research Company that provides Extended reality market statistics, including extended reality industry global market size, regional shares, competitors with an extended reality market share, detailed extended reality market segments, market trends, and opportunities, and any further data you may need to thrive in the extended reality industry. This extended reality market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.